Moberg Pharma´s interim report January - June 2022
ANOTHER AGREEMENT IN PLACE AND PATIENT ENROLLMENT ONGOING IN THE NORTH AMERICAN PHASE 3 STUDYSIX MONTH PERIOD (JAN-JUN 2022) · EBITDA SEK -9.1 million (-8.9) * · Operating profit (EBIT) SEK -10.4 million (-10.2) * · Profit after tax SEK -8.3 million (-8.3) * · Total profit SEK -8.3 million (15.3) ** · Diluted earnings per share SEK -0.13 (0.36) · Cash and cash equivalents amounted to SEK 160.0 million (124.2) SECOND QUARTER (APR-JUN 2022) · EBITDA SEK -4.3 million (-3.5) * · Operating profit (EBIT) SEK -4.9 million (-4.1) * · Profit after tax SEK -3.9